

314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

> Tel.: + 91 22 6663 5456 Fax: +91 22 6663 5460

E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

August 02, 2022

The Listing Department
BSE Limited
Phiroz Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Ref: Security Code No. 530233

Dear Sir/Madam,

Sub: Outcome of meeting of Board of Directors of Auro Laboratories Limited dated August 02, 2022

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. **Tuesday, August 02, 2022)** transacted the following business:

1. Considered and approved the Unaudited Financial Results of the Company for the quarter ended on June 30, 2022 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the quarter ended on June 30, 2022
- Limited Review Report received from the Statutory Auditors of the Company

The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 03.05 P.M.

The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking you, Yours Faithfully,

For, Auro Laboratories Limited

(Siddhartha Deorah) Whole Time Director

JUVILLIA

DIN: 00230796

Encl: A/a

AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office: K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022					
Sr.	Darticulare	Quarter Ended			Year Ended
No.		30.06.2022 (Unaudited)	31.03.2022 (Ref. Note 4)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Revenue from Operations	1,118.52	1,788.35	1,053.00	5,086.5
2	Other Income	5.10	28.16	49.54	109.2
3	Total Income (1 + 2)	1,123.62	1,816.51	1,102.54	5,195.8
4	Expenses				
	a. Cost of raw material consumed	700.60	22.00		
	b. Purchase of Stock-in-trade	792.53	1,209.23	779.27	3,373.88
	c. Changes in inventories of finished goods, work-in-progress		-	1.09	2.40
	and stock in trade	(70.86)	67.32	(158.71)	(98.16
	d. Employee benefits expense				
_	e. Finance Cost	115.34	188.68	137.53	624.00
	f. Depreciation and amortisation expenses	26.16	39.63	11.09	82.64
_	g. Other Expenses	25.00	23.72	26.00	101.72
	Total Expenses (4)	223.99	232.94	155.80	721.98
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	1,112.16	1,761.52 54.99	952.07 150.47	4,808.43
6	Exceptional items		1136164511		
7	Profit / (Loss) before tax (5 ± 6)	11.46	54.00	199.10	
8	Tax expense	11.40	54.99	150.47	387.40
	(a) Current tax expenses for current year	3.19	13.25	42.00	444.44
	(b) MAT credit (where applicable)	3,19	13.25	43.82	106.69
	(c) Deferred tax		(3.76)		(2.70
9	Profit / (Loss) for the period from continuing operation (7±8)	8.27	45.50	106.65	(3.76
10	Profit / (Loss) for discontinuing operations	0.27	45.50	106.65	284.47
11	Tax expense of discontinuing operations				
12	Profit / (Loss) for discontinuing operation (after tax) (10 ± 11)				•
-	Profit / (Loss) for the period (after tax) (9 ± 12)	8.27	45.50	106.65	284.47
	Other Comprehensive Income	(0.07)	11.14	8.53	11.14
15	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)] (13 ± 14)	8.20	56.64	115.18	295.61
16	Paid-up equity share capital	623.25	623.25	623.25	623,25
	(Face value of Rs. 10 each)		-	020,20	949,69
17	Other Equity				2,528.85
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):				
	(a) Basic	0.13	0.73		
_	(b) Diluted	0.13	0.73	1.71	4.56

Notes on financial results:-

- The above unaudited financial results for the quarter ended June 30, 2022 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on August 02, 2022.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- Limited Review has been carried out by the Statutory Auditors of the Company.
- 4) Figures of the Quarter ended on March 31, 2022 are the balancing figures between audited figures in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

(SIDDHARTHA DEORAH) WHOLE TIME DIRECTOR DIN: 00230796

Place : Mumbai Date : 02/08/2022





To, The Board of Directors, Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended June 30, 2022, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants

Sampat Khurdia

Partner

Membership No. 033615 Firm Reg. No. 120263W

Place: Mumbai

Date: 2nd August 2022

UDIN: 22033615AOAXCP6502